Additional file 1: Table S1: The World Health Organization (WHO) Trial Registration Data Set for the SIMPLER study.

Data category	Information
Primary Registry and Trial	Australian New Zealand Clinical Trials Registry
Identifying Number	ACTRN12617001060336
Date of Registration in	20/07/2017
Primary Registry	
Secondary Identifying	Universal Trial Number: U1111-1199-0894
Numbers	
Source(s) of Monetary or	National Health and Medical Research Council (NHMRC) Partnership
Material Support	Centre for Dealing with Cognitive and Related Functional Decline in
	Older People (the Cognitive Decline Partnership Centre or CDPC)
Primary Sponsor	Centre for Medicine Use and Safety, Faculty of Pharmacy and
	Pharmaceutical Sciences, Monash University
	381 Royal Parade, Parkville VIC 3052, Australia
Secondary Sponsor(s)	None
Contact for Public	Dr Janet Sluggett
Queries	Centre for Medicine Use and Safety, Faculty of Pharmacy and
	Pharmaceutical Sciences, Monash University
	381 Royal Parade, Parkville VIC 3052, Australia
	Phone: +61 3 99039533
	Email: janet.sluggett@monash.edu
Contact for Scientific	Dr Janet Sluggett
Queries	Centre for Medicine Use and Safety, Faculty of Pharmacy and
	Pharmaceutical Sciences, Monash University
	381 Royal Parade, Parkville VIC 3052, Australia
	Phone: +61 3 99039533
	Email: janet.sluggett@monash.edu
Public Title	SImplification of Medications Prescribed to Long tErm care Residents
	(SIMPLER)
Scientific Title	SImplification of Medications Prescribed to Long tErm care Residents
	(SIMPLER): a cluster randomised trial of a structured process to
	reduce unnecessary medication regimen complexity

Countries of Recruitment	Australia
Health Condition(s) or	Polypharmacy, Medication incidents, Dementia, Cognitive
Problem(s) Studied	impairment, Falls, Hospitalisation, Frailty
Intervention(s)	Medications taken by residents in the intervention arm will be
	assessed once using a structured tool to identify opportunities to
	reduce medication regimen complexity. Residents in the comparison
	group will receive routine care.
Key Inclusion and	Key Inclusion Criteria: Permanent residents of aged care facilities who
Exclusion Criteria	are aged ≥18 years, English-speaking and taking at least one
	medication.
	Key Exclusion Criteria: Residents estimated by RACF staff to have less
	than three months to live and those deemed by facility staff to be
	medically unstable (e.g. experiencing delirium) will be excluded.
	Residents may also be excluded at the discretion of RACF staff and
	their treating clinicians.
	English-speaking residents who are unable to participate in the Short
	Assessment of Patient Satisfaction (SAPS) are still eligible for inclusion
	in the study.
Study Type	in the study. Study type: Interventional
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used)
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff at each RACF will be blinded to the allocation at the time of resident
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff at each RACF will be blinded to the allocation at the time of resident recruitment. Due to the nature of the intervention, it will not be
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff at each RACF will be blinded to the allocation at the time of resident recruitment. Due to the nature of the intervention, it will not be possible to blind study nurses, residents, RACF staff, clinicians and
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff at each RACF will be blinded to the allocation at the time of resident recruitment. Due to the nature of the intervention, it will not be possible to blind study nurses, residents, RACF staff, clinicians and study investigators to the intervention assignment throughout the
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff at each RACF will be blinded to the allocation at the time of resident recruitment. Due to the nature of the intervention, it will not be possible to blind study nurses, residents, RACF staff, clinicians and study investigators to the intervention assignment throughout the study period.
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff at each RACF will be blinded to the allocation at the time of resident recruitment. Due to the nature of the intervention, it will not be possible to blind study nurses, residents, RACF staff, clinicians and study investigators to the intervention assignment throughout the study period. Methods used to generate the sequence in which subjects will be
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff at each RACF will be blinded to the allocation at the time of resident recruitment. Due to the nature of the intervention, it will not be possible to blind study nurses, residents, RACF staff, clinicians and study investigators to the intervention assignment throughout the study period. Methods used to generate the sequence in which subjects will be paired
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff at each RACF will be blinded to the allocation at the time of resident recruitment. Due to the nature of the intervention, it will not be possible to blind study nurses, residents, RACF staff, clinicians and study investigators to the intervention assignment throughout the study period. Methods used to generate the sequence in which subjects will be randomised (sequence generation): Aged care facilities will be paired by the study investigators based on location (i.e. metropolitan or
Study Type	in the study. Study type: Interventional Study design: Matched-pair, cluster randomised controlled trial Masking: Open (masking not used) Intervention assignment: Parallel Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures): Study nurses, residents and staff at each RACF will be blinded to the allocation at the time of resident recruitment. Due to the nature of the intervention, it will not be possible to blind study nurses, residents, RACF staff, clinicians and study investigators to the intervention assignment throughout the study period. Methods used to generate the sequence in which subjects will be randomised (sequence generation): Aged care facilities will be paired by the study investigators based on location (i.e. metropolitan or rural) and number of beds. One RACF within each pair will be

	comparison (usual care) group. An independent
	pharmacoepidemiologist will perform the randomisation using the
	computerised random number generator within SAS (SAS Institute,
	Cary, NC). Block randomisation will be used to ensure an equal
	number of intervention and comparison groups.
Date of First Enrollment	24/04/2017
Target Sample Size	194 residents
Recruitment Status	Recruiting
Primary Outcome(s)	Primary Outcome: Total number of charted medication administration
	times over a 24 hour period for regular medications.
	Metric/method of measurement: Determined from medication data
	extracted by the study nurses.
	Timepoint: Baseline, and at 4 months after study entry.
Key Secondary Outcomes	Secondary Outcome 1: Total number of charted medication.
	administration times over a 24 hour period for regular medications.
	Metric/method of measurement: Determined from medication data
	extracted by the study nurses.
	Timepoint: 8 and 12 months after study entry, to assess the
	sustainability of the intervention.
	Secondary outcome 2: Duration of time spent administering
	medications.
	Metric/method of measurement: Determined from medication data
	extracted by the study nurses and from data collected during a
	concurrent time-motion study.
	Timepoint: Baseline, and at 4 and 8 months after study entry.
	Secondary outcome 3: Costs associated with medication
	administration.
	Metric/method of measurement: Determined from medication data
	extracted by the study nurses and from data collected during a
	concurrent time-motion study.
	Timepoint: Baseline, and at 4 and 8 months after study entry.

Secondary outcome 4: Resident satisfaction.
Metric/method of measurement: Assessed using the 7-item revised
version of the Short Assessment of Patient Satisfaction (SAPS) scale.
Timepoint: Baseline, and at 4 months after study entry.
Secondary outcome 5: Quality of life.
Metric/method of measurement: Assessed by a staff informant using
the 15-item Quality of Life in Alzheimer's Disease (QoL-AD) scale
adapted for residents of aged care facilities.
Timepoint: Baseline, and at 4 months after study entry.
Secondary outcome 6: Change in medication incidents (e.g.
prescribing errors, pharmacy dispensing errors identified by facility
staff, client errors, administration errors or adverse drug reactions).
Metric/method of measurement: Determined from the electronic
records maintained by the aged care provider organisation.
Timepoint: Baseline, and at 4, 8, 12 and 24 months after study entry.
Secondary outcome: Number of falls.
Metric/method of measurement: Determined from the electronic
records maintained by the aged care provider organisation.
Timepoint: Baseline, and at 4, 8, 12 and 24 months after study entry.
Secondary outcome 8: All-cause overnight hospitalisations.
Metric/method of measurement: Determined from the electronic
records maintained by the aged care provider organisation.
Timepoint: Baseline, and at 4, 8, 12 and 24 months after study entry.
Secondary outcome 9: All-cause mortality.
Metric/method of measurement: Determined from the electronic
records maintained by the aged care provider organisation and/or
records maintained by the Government of South Australia Consumer
and Business Services: Births, Deaths and Marriages.

Timepoint: Baseline, and at 4, 8, 12, 24 and 36 months after study
entry.